|Day Low/High||1.72 / 1.80|
|52 Wk Low/High||1.36 / 6.94|
ImmunoPulse™ IL-12 May Lead to Increased CD8+ T-Cell Infiltration in Patients with Squamous Cell Carcinoma of the Head and Neck, Suggesting That It May Prime Responses to Anti-PD-1 Blockade
The combination of OncoSec's ImmunoPulse™ IL-12 and pembrolizumab is the first clinical trial to use this assay to select specific patients, who are unlikely to respond to monotherapy with anti-PD-1 agents
Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.
Preclinical findings demonstrate that intratumoral electroporation activates tumor neoantigen-specific immune responses